The ‘Biologics Fill / Finish Service Providers, 2019-2030

narender.shukla@rootsanalysis.co

198
views

Key Inclusions

§ A detailed assessment of the current market landscape,including information on drug developer(s), phase of development (marketed,clinical and preclinical / discovery stage) of lead candidates, target immunecheckpoints, their respective mechanisms of action (inhibitory or stimulatory), type of therapeutic modality used (monoclonal antibody, antibodyfragment, small molecule and others), route of administration (intravenous,subcutaneous, oral and others), target disease indication, target therapeuticarea and type of therapy (monotherapy, combination therapy and both).

§ A detailed analysis of more than 590 completed, ongoing andplanned clinical studies of next generation immune checkpoint inhibitors andstimulators, highlighting prevalent trends across various relevant parameters,such as current trial status, trial registration year, phase of development,study design, leading industry sponsors / collaborators (in terms ofnumber of trials conducted), trial focus, type of target, target indication(s),target therapeutic area(s), enrolled patients population and regionaldistribution.

§ Detailed profiles of developers of next generation immunecheckpoint modulators (shortlisted on the basis of the number of pipelineproducts), featuring an overview of the company, its financialinformation (if available), a detailed description of its productportfolio and recent collaborations. In addition, each profile includes aninformed future outlook.

§ An in-depth analysis of more than 490 grants that have beenawarded to research institutes engaged in next generation immune checkpointtherapy-related projects, in the period between 2016 and 2019 (tillNovember), including analysis based on important parameters, such as year ofgrant award, amount awarded, administration institute center, funding institutecenter, support period, type of grant application, purpose of grant award,grant mechanism, popular target immune checkpoints, responsible study section,focus area, prominent program officers, and type of recipient organizations. Italso features a detailed analysis based on the types of target immunecheckpoints and therapeutic areas, along with a multivariate grantattractiveness analysis based on parameters, such as grant amount, supportperiod, type of grant application and number of disease indications underinvestigation.

§ An analysis of the partnerships that have been establishedin the recent past, covering R&D collaborations, licensingagreements (specific to affiliated technology platforms and productcandidates), product development and commercialization agreements, clinicaltrial agreements, manufacturing agreements, mergers and acquisitions,manufacturing and service agreements, and other relevant types of deals.

§ An insightful competitiveness analysis of biologicaltargets, featuring a [A] three-dimensional bubble representation thathighlights the targets that are being evaluated for next generation immunecheckpoint therapy development, taking into consideration the number of leadmolecules based on a particular target, phase of development of candidatetherapies, number of grants and number of publications [B] a five-dimensionalspider-web analysis, highlighting the most popular immune checkpoint targets.

§ An analysis of the big biopharma players engaged in thisdomain, featuring a heat map based on parameters, such as number of therapiesunder development, target disease indications, partnership activity and targetportfolio.

§ Informed estimates of the existing market size and thefuture opportunity for contract fill / finish services for biologics, over thenext decade. Based on multiple parameters, such as biopharmaceutical contract servicesmarket size, share of fill / finish services and their likely outsourcingprofile, we have provided informed estimates on the evolution of the market forthe period 2019-2030.

The report also features thelikely distribution of the current and forecasted opportunity across importantmarket segments, mentioned below:

§ Types of Primary Packaging Containers

§ Ampoules

§ Cartridges

§ Syringes

§ Vials

§ Types of Biologics

§ Peptides / proteins

§ Antibodies

§ Vaccines

§ Cell therapies

§ Gene therapies

§ Viral products

§ Oligonucleotides

§ Others

§ Company Size

§ Small-sized

§ Mid-sized

§ Large / very large

§ Scale of Operation

§ Preclinical

§ Clinical

§ Commercial

§ Key Therapeutic Areas

§ Cancer

§ Infectious diseases

§ Autoimmune diseases

§ Cardiovascular diseases

§ Other indications

§ Key Geographical Regions

§ North America (US, Canada)

§ Europe (UK, France, Germany, Italy, Spain and rest of theEurope)

§ Asia-Pacific (Japan, China, South Korea, India andAustralia)

Thereport features inputs from a number of eminent industry stakeholders,according to whom, “Currently, majority of biologics are being filled in vials,however, the scenario is likely to change in the future due to the growingdemand and preference for self-administration devices.” The report featuresdetailed transcripts of discussions held with the following experts:

§ AlesSima, Business Development Manager, oncomed manufacturing

§ GregorKawaletz, Chief Commercial Officer, IDT Biologika

§ JosVergeest, International Business Developer, HALIX

§ PurushottamSingnurkar, Research Director and Head of Formulation Development, Syngene International

To request samplepages, please visit this link

Key QuestionsAnswered

§ Who are the leading industry players engaged in the contractfill / finish services market for biologics?

§ Which are the prominent packaging formats used forbiologics?

§ Where are the players setting up new facilities or addinginfrastructure across the globe?

§ Which partnership models are commonly adopted bystakeholders in this industry?

§ What is the current fill / finish supply?

§ What is the demand for contract fill / finish services forbiologics?